Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer

To assess the effects of systemic therapies on the prevention or management of AIMSS in patients with Stage I-III hormone receptor-positive breast cancer.

This is a protocol.

You may also be interested in:

Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer
Bone-modifying agents for the prevention of bone loss in women with early or locally advanced breast cancer: a systematic review and network meta-analysis
Angiotensin converting enzyme (ACE) gene polymorphism (ACEI/D) in hypertensive adults with ACE inhibitor-induced cough
Prophylactic colony-stimulating factors to prevent infectious complications in patients with breast cancer undergoing chemotherapy
Ovarian suppression with LHRH agonists (such as goserelin) for treating premenopausal women with early breast cancer

Health topics:

Cancer > Breast > Endocrine therapy

Cancer > Breast > Prevention & treatment of treatment-related harms

Published:

5 November 2018

Authors:

Roberts KE, Rickett K, Chatfield MD, Woodward NE

Primary Review Group:

Breast Cancer Group

See the full Review on

the Cochrane Library

►

Print
PDF
Citation
Roberts KE, Rickett K, Chatfield MD, Woodward NE. Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer. Cochrane Database of Systematic Reviews 2018, Issue 11. Art. No.: CD013167. DOI: 10.1002/14651858.CD013167

Don't show again

What role do you identify with the most?

Patient or care giver

Health practitioner

Researcher

Policy Maker

We are collecting information on visitors to our website to ensure Cochrane resources meet the needs of our users. Your data will be anonymised for processing, will be stored securely, and will not be shared with any third parties.